Press releases
- Agilent to Announce First-Quarter Fiscal Year 2023 Financial Results Feb. 28
- Agilent to Collaborate with Quest Diagnostics to Extend Access to the Agilent Resolution ctDx FIRST Liquid Biopsy Test
- Agilent Included in Just Capital’s 2023 List of Most Just Companies
- Agilent Authorizes $2 Billion Share Repurchase Program
- Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics
- Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
- Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
- Agilent to Present at Goldman Sachs and J.P. Morgan Healthcare Conferences
- Agilent Resolution ctDx FIRST Receives FDA Approval as a Liquid Biopsy Companion Diagnostic Test for Advanced Non-small Cell Lung Cancer
- Agilent Again Named to Newsweek’s List of America’s Most Responsible Companies
More ▼
Key statistics
On Wednesday, Agilent Technologies Inc (0HAV:LSE) closed at 154.02, -3.90% below its 52-week high of 160.27, set on Dec 13, 2022.
52-week range
Markit short selling activity
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 153.16 |
Average volume | 3.09k |
---|---|
Shares outstanding | 295.86m |
Free float | 294.19m |
P/E (TTM) | 36.93 |
Market cap | 45.71bn USD |
EPS (TTM) | 4.18 USD |
Annual div (ADY) | 0.90 USD |
---|---|
Annual div yield (ADY) | 0.59% |
Div ex-date | Dec 30 2022 |
Div pay-date | Jan 25 2023 |
Data delayed at least 20 minutes, as of Feb 08 2023 17:05 GMT.
More ▼